A lull in FDA Covid-19 test authorisations
Just as demand for coronavirus tests is peaking, the US regulator has a quiet week.
Qiagen enters the T-cell testing fray
At least two groups have posted early data on T-cell tests for Covid-19; now Qiagen has licensed tech to make its own.
US cuts fees for Covid-19 tests
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Orthopaedics companies’ nightmare quarter
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
The Thermo-Qiagen saga comes to an end
Qiagen is one of the few medtechs to do well out of the Covid-19 pandemic. From Thermo Fisher’s point of view it has done too well.
A Covid-19 threat to business acquisitions
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
Thermo Fisher buys Qiagen after all
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
2019 was all about execution for smaller device makers
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
